Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab

Natalizumab (NAT) was the first disease modifying therapy used for the treatment of relapsing-remitting multiple sclerosis (MS) that was designed with a specific mechanism of action that targets an important step of the MS immunopathology, directly blocking the T lymphocyte intrusion in the central...

Full description

Bibliographic Details
Main Authors: Smaranda Maier, Mihaela Simu, Adina Hutanu, Laura Barcutean, Septimiu Voidazan, Zoltan Bajko, Anca Motataianu, Irina Lata, Rodica Balasa
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Brain Sciences
Subjects:
multiple sclerosis
natalizumab
mechanism of action
pro and anti-inflammatory cytokines
Online Access:https://www.mdpi.com/2076-3425/10/11/802

Similar Items

Similar Items